8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2004 (August 5, 2004)

AMSURG CORP.

(Exact Name of Registrant as Specified in its Charter)

Tennessee	000-22217	62-1493316
(State or other jurisdiction of	(Commission	(I.R.S. employer
incorporation or organization)	File Number)	identification no.)

20 Burton Hills Boulevard
Nashville, Tennessee	37215
(Address of principal executive offices)	(Zip code)

(615) 665-1283
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former name or former address, if changed since last report)

TABLE OF CONTENTS

	Item 5. Other Events and Required FD Disclosure
SIGNATURES
INDEX TO EXHIBITS
EX-99 PRESS RELEASE 08/05/04

Item 5. Other Events and Required FD Disclosure

     A press release issued by AmSurg Corp. on August 5, 2004 is furnished herewith as Exhibit 99.

2

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMSURG CORP.
By:	/s/ Claire M. Gulmi
	Claire M. Gulmi
	Senior Vice President and Chief Financial Officer (Principal Financial and Duly Authorized Officer)

Date: August 5, 2004

3

INDEX TO EXHIBITS

Exhibit
Number	Description
99	Press release dated August 5, 2004

4

EX-99

                                                                      EXHIBIT 99
PRESS RELEASE


         AMSURG CORP. TO RECORD $0.14 PER DILUTED SHARE GAIN ON SALE OF
                              OPHTHALMOLOGY CENTER

                                ----------------

             PROVIDES UPDATED 2004 EARNINGS GUIDANCE AND ESTABLISHES
                             2005 EARNINGS GUIDANCE

            NASHVILLE, Tenn. (August 5, 2004) - Ken P. McDonald, President and
Chief Executive Officer of AmSurg Corp. (Nasdaq: AMSG), today announced the sale
of its interest in an ophthalmology surgery center for $12,500,000 to the
center's physician partners as of August 1, 2004. As a result of the
transaction, AmSurg expects to record a $0.14 per diluted share gain on the
sale, and the gain and the net earnings of the center through the date of the
sale will be reflected in discontinued operations for the third quarter and nine
months reporting periods.

            Mr. McDonald remarked, "This center produced net earnings of $0.03
per diluted share for the first seven months of 2004, which will now be
classified as earnings from discontinued operations. The center was projected to
contribute $0.02 per diluted share for the remainder of 2004. Due to the sale of
this center, our guidance for results from continuing operations will be reduced
by $0.05 per diluted share. This reduction is composed of the $0.03 of
historical earnings reflected as discontinued operations and the $0.02 of
earnings that were projected for the remainder of the year. As a result, our
guidance for 2004 adjusted net earnings per diluted share from continuing
operations is $1.11 to $1.14, compared to the previous range of $1.16 to $1.19.
Adjusted net earnings, as previously disclosed, exclude a loss of $1,100,000 on
a long-term note receivable incurred in the second quarter of 2004. Net earnings
per diluted share from continuing operations for 2004, which include the loss on
the note receivable, are projected to be $1.09 to $1.12.

            "Due to the strength of our new center development and acquisition
activities, the sale of our interest in this center has not changed our internal
earnings targets for 2005. We today establish our guidance for net earnings per
diluted share from continuing operations for 2005 in a range of $1.39 to $1.43.
This range represents anticipated growth of 20% from our original guidance for
2004, consistent with our long-term growth objectives for net earnings per
diluted share from continuing operations. This range also represents anticipated
growth of 25% from our new guidance for 2004 adjusted net earnings per diluted
share from continuing operations."

            Mr. McDonald added, "With our strong acquisition and development
pipeline, we are confident of our opportunities and pleased to establish our
earnings guidance for 2005 in line with our long-term growth objectives."








                                     -MORE-





AMSG Reports Sale of Center
Page 2
August 5, 2004


            The information contained in the preceding paragraphs is
forward-looking information, and the attainment of these targets is dependent
not only on AmSurg's achievement of its assumptions discussed above, but also on
the risks and uncertainties listed below that could cause actual results,
performance or developments to differ materially from those expressed or implied
by this forward-looking information.

            This press release contains forward-looking statements. These
statements, which have been included in reliance on the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, involve risks and
uncertainties. Investors are hereby cautioned that these statements may be
affected by the important factors, among others, set forth in AmSurg's filings
with the Securities and Exchange Commission, and, consequently, actual
operations and results may differ materially from the results discussed in the
forward-looking statements. Factors that might cause such a difference include,
but are not limited to, the Company's ability to enter into partnership or
operating agreements for new practice-based ambulatory surgery centers; its
ability to identify suitable acquisition candidates and negotiate and close
acquisition transactions, including centers under letter of intent; its ability
to obtain the necessary financing or capital on terms satisfactory to the
Company to execute its expansion strategy; its ability to generate and manage
growth; its ability to contract with managed care payers on terms satisfactory
to the Company for its existing centers and its centers that are currently under
development; its ability to obtain and retain appropriate licensing approvals
for its existing centers and centers currently under development; its ability to
minimize start-up losses of its development centers; the ability of its
physician partners to recruit additional physicians to their practices; its
ability to maintain favorable relations with its physician partners; changes in
the medical staff at its centers; changes in the rate setting methodology,
payment rates, payment policies and the list of covered surgical procedures for
ambulatory surgery centers by the Centers for Medicare & Medicaid Services; the
risk of legislative or regulatory changes that would establish uniform rates for
outpatient surgical services, regardless of setting; risks associated with the
Company's status as a general partner of limited partnerships; the Company's
ability to maintain its technological capabilities in compliance with regulatory
requirements; risks associated with the valuation and tax deductibility of
goodwill; the risk of legislative or regulatory changes that would prohibit
physician ownership in ambulatory surgery centers; and the Company's ability to
obtain the necessary financing to fund the purchase of its physician partners'
minority interest in the event of a regulatory change that would require such a
purchase. AmSurg disclaims any intent or obligation to update these
forward-looking statements.

            AmSurg Corp. develops, acquires and manages physician practice-based
ambulatory surgery centers in partnership with surgical and other group
practices. At June 30, 2004, AmSurg owned a majority interest in 117 centers and
had 13 centers under development.


                                           Contact:
                                                     Claire M. Gulmi
                                                     Senior Vice President and
                                                     Chief Financial Officer
                                                     (615) 665-1283



                                      -END-